To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg5/8 cls
CorMedix Inc. (NYSE-M:CRMD)Roth Capital PartnersScott HenryDowngradeNeutral (from buy)-6%$7.15
Henry downgraded after a significant run up in the share price to about $8 from about $1 in January. He attributes the rise to regulatory designations with the potential to speed up clinical progress and speculation surrounding the appointment of Evercore

Read the full 577 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers